. The emerged significance of UCP-2 expression in the liver. The solid line is the pathway that has been established, whereas the dashed line is the pathway that needs further confirmation.
To the Editor: The recently published review by Saleh et al. about the role of uncoupling protein-2 (UCP-2) in regulation of lipid metabolism has provided an amazing assembly of current knowledge in this subject [1] . However, in this review the role of UCP-2 in the liver has not been fully addressed although it has been discussed briefly in the section of reactive oxygen species (ROS) production. Normally the UCP-2 gene is not expressed in murine liver parenchymal cells except Kupffer cells and so far no UCP-2 expression in adult human liver has been reported [1] . However, accumulating data constantly show the up-regulation of UCP-2 expression in mouse hepatocytes that is associated with obesity (ob/ob mice) and high-fat feeding [2] . Moreover, lines of evidence suggest that UCP-2 can act with other intracellular signalling systems in the liver and exert profound effects more than regulating ROS generation only [1, 2] . Considering that in both humans and rodents a great portion of UCP2 expression occurs in skeletal muscle, adipose tissue, and islet beta cells that are components of the insulin action network [2] , and that liver, which is predominant in maintaining in vivo fuel homeostasis, is a classic target of insulin action [3] , one should consider the possibility of UCP-2 expression in both human and murine liver parenchymal cells. As such, this letter argues for an "on the alert role" of UCP-2 in hepatocytes to deal with high-fat challenge and its possible correlation with glucose metabolism.
In Type 2 diabetes both glucose and fat metabolisms are deranged. The involvement of UCP-2 is indicated by the observations that the UCP-2 gene is linked to hyperinsulinaemia and obesity, and in humans it has the highest degree of positive association with BMI among other UCPs [1] . In ob/ob mice, highly expressed UCP-2 is positively correlated with increased mitochondrial proton (H+) leak and this could promote depletion of ATP stores within hepatocytes [4] . On the other hand, 5′-AMP-activated protein kinase (AMPK) is also involved in Type 2 diabetes due to its role as a "fuel gauge" [5] . Activated AMPK phosphorylates serine residues in targeting proteins, and down-regulates acetyl-CoA carboxylase (ACC), the enzyme catalyzing the first step of fatty-acid synthesis, and 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase, the enzyme catalyzing the key step in isoprenoid and sterol biosynthesis [5] . Since decreased malonyl-CoA liberates carnitine palmitoyltransferase-I (CPT I) from inhibition, the net result of AMPK activation in the liver is to reduce lipid anabolism but enhance fatty acid mitochondrial β-oxidation. Whether there is any correlation between UCP-2 activity and AMPK signalling system in hepatocytes has not been investigated. However, since AMPK is potently stimulated by depletion of intracellular ATP (or increased AMP:ATP ratio), which is a result of UCP-2 expression in the liver [4, 5] , a possible functional link between these two intracellular systems emerged.
In addition to the fat-stimulated high expression of UCP-2 and its plausible resultant AMPK activation, further study suggests that this putative functional link could be extended to de novo glucose synthesis (gluconeogenesis) since activated AMPK abolishes the suppression of phosphoenolpyruvate carboxykinase (PEPCK) mRNA by glucose [6] . Although the prevailing view believes that activated AMPK reduces hepatic gluconeogenesis via down-regulation of gluconeogenic enzymes such as PEPCK, fructose-1,6-bisphosphatase (F-1,6-BPase), and glucose-6-phosphatase (G-6-P) [5] , this might not be a general case because AMPK is activated during hypoglycaemia, exercise, and hypoxia [5] , whereas gluconeogenesis is enhanced in the first two circumstances but decreased in the third condition [3] . This discrepancy suggests that the effect of AMPK on gluconeogenesis might not be a direct action but a distal regulation that could be compromised with in vivo situations. Under the circumstance of high fat availability its net effect could become enhancing hepatic gluconeogenesis rather than decreasing it.
Gluconeogenesis contributes substantially to fasting hyperglycaemia in Type 2 diabetes and it has been known for a long time that fat can stimulate hepatic gluconeogenesis either in vitro or in vivo [3] . In addition, the rate of gluconeogenesis correlates positively with the fluctuation of plasma NEFA concentrations. The mechanism responsible for this intrinsic correlation remains unknown. It has been suggested that "fuel selection", which predominantly occurs at the transcriptional level, could play an essential role [7] . It is noticed that there are at least six binding sites in UCP-2 gene promoter that have also been identified within the promoter region of genes encoding PEPCK, F-1,6-Bpase, and G-6-P [3, 8] . These shared binding motifs are subject to the regulation from specificity protein-1 (Sp-1), activator protein-1 (AP-1), CCAAT/enhancer binding protein-β (C/EBP-β), and cAMP response element binding protein-1 (CREB-1) [3, 8] , rendering the possibility of simultaneous regulation of expression of both UCP-2 and gluconeogenic enzyme genes although the UCP-2 gene promoters between human and mouse show moderate homology only. Although further study is needed, the speculated connection between UCP-2 and AMPK functions in the liver under high fat availability provide, at least partially, a potential mechanism by which fatty acid stimulates hepatic gluconeogenesis in mammals.
In conclusion, it seems that the physiological significance of UCP-2 gene expression in hepatocytes, although it occurs only in certain circumstances, might not be limited to ROS generation only. When the body is facing a high-fat challenge such as in obesity or high-fat feeding, the expression of UCP-2 could serve as a means to discharge fat-associated energy by not only enhancing proton leak but also transforming fuel configuration which is achieved by stimulating gluconeogenesis. As such, a loop between fat and glucose metabolism is formed (Fig. 1) . To further elucidate the 'bona fide' role of UCP-2 in hepatocytes, a tissue-specific knockout strategy rather than global null-mouse model is suggested since transgenic studies have shown that phenotypes resulting from global knockout model tends to be confounded by in vivo compensation mechanism whereas tissue specific disruption of the UCP-2 gene could reveal its natural attribute.
S. Song Department of Pharmacology, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, NY 10032, USA
